Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Conditions
- Head and Neck Squamous Cell Carcinoma
- Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Recurrent Nasopharynx Carcinoma
- Recurrent Salivary Gland Carcinoma
- Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary
- Stage III Major Salivary Gland Carcinoma
- Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage III Nasopharyngeal Carcinoma
- Stage IV Nasopharyngeal Carcinoma
- Stage IVA Major Salivary Gland Carcinoma
- Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVB Major Salivary Gland Carcinoma
- Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
- Stage IVC Major Salivary Gland Carcinoma
- Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma
Interventions
- OTHER: Laboratory Biomarker Analysis
- BIOLOGICAL: Pembrolizumab
- DRUG: Vorinostat
Sponsor
University of Washington
Collaborators